<DOC>
	<DOCNO>NCT01305122</DOCNO>
	<brief_summary>This multicenter prospective study:2 independant cohort patient OMS grade II glioma follow 5 year . - cohort A : patient first-line treatment ( surgery , radiotherapy chemotherapy ) - cohort B : patient disease simple monitoring . The primary endpoint evaluate impact tumor treatment neurocognitive function quality life , use validate standard test .</brief_summary>
	<brief_title>Tumor Treatments Impact Neurocognitive Functions Quality Life Patients With OMS Grade II Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<criteria>OMS grade II glioma sign informed consent age &gt; =18 IK &gt; =80 % ability read , write undertand French glioma localize brainstem neurologic psychiatric disease history malignancy , curatively treat insitu carcinoma cervix basal cell carcinoma skin , curatively treat cancer sign recurrence within 5 year prior randomization neuroleptic concomitant treatment pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Glioma</keyword>
	<keyword>Neurocognitive function</keyword>
</DOC>